Cipla Ltd (CIPLA) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Cipla delivered steady revenue of 6,957 crores with a 25.6% EBITDA margin.
- One India business achieved 6% YoY growth, exceeding 3,000 crores in revenue for the first time in Q1.
- US business sustained momentum despite price erosion in a major product.
- Consumer Healthcare business maintained strong growth with leading brands like Nicotex and Ciplodine.
- One Africa business grew by 11% YoY in USD terms.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.